Last reviewed · How we verify
IV thyroxin
At a glance
| Generic name | IV thyroxin |
|---|---|
| Also known as | elthyroxin, thyroxin, euthrux |
| Sponsor | Rambam Health Care Campus |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (PHASE2)
- Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease (PHASE1, PHASE2)
- The Role of Immunomodulatory Treatment in Success of ICSI in Patients With Autoimmune Thyroiditis (PHASE2)
- Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer (PHASE1)
- Thyroid and Adrenocortical Hormone Replacement in Organ Donors (NA)
- Wound Complications in Head and Neck Surgery
- Evaluation of the Efficacy and Safety of Levothyroxine in Brain Death Organ Donors: a Randomized Controled Trial (PHASE4)
- Selenium Supplementation in Pregnancy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV thyroxin CI brief — competitive landscape report
- IV thyroxin updates RSS · CI watch RSS
- Rambam Health Care Campus portfolio CI